HIF-1: upstream and downstream of cancer metabolism

Current Opinion in Genetics and Development

Volumn 20, Issue 1, 2010, Pages 51-56

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; GLYCOLYTIC ENZYME; HYPOXIA INDUCIBLE FACTOR 1; LACTIC ACID; PROTEIN BNIP3; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVIC ACID;

AEROBIC METABOLISM; AUTOPHAGY; CANCER CELL; CELL METABOLISM; CELL SURVIVAL; GENETIC TRANSCRIPTION; GLYCOLYSIS; HUMAN; HYPOXIA; MITOCHONDRION; OXIDATION REDUCTION STATE; POSITIVE FEEDBACK; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

DISEASE PROGRESSION; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; TRANS-ACTIVATORS;

EID: 76049100577     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2009.10.009     Document Type: Review

References (47)

1. Gatenby R.A., and Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
2. Vaupel P., Mayer A., and Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 381 (2004) 335-354
3. •] performed ChIP-chip (chromatin immunoprecipitation and mRNA microarray) analysis to identify direct target genes of HIF-1 and HIF-2. The majority of hypoxia-induced genes contained HIF-1 binding sites and expression was dependent on HIF-1α expression. HIF-2α bound to many of the same genes, but knockdown of HIF-2α levels did not affect gene expression. Hypoxia-repressed gene expression was also HIF-1α-dependent but did not involve direct HIF-1α binding to target genes.
4. •].
5. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, in press.
6. 2 tension. Proc Natl Acad Sci U S A 92 (1995) 5510-5514
7. Kaelin Jr. W.G., and Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30 (2008) 393-402
8. Guzy R.D., and Schumacker P.T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91 (2006) 807-819
9. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12 (1998) 149-162
10. Vander Heiden M.G., Cantley L.C., and Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009) 1029-1033
11. Ullah M.S., Davies A.J., and Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem 281 (2006) 9030-9037
12. Sonveaux P., Végran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., De Saedeleer C.J., Kennedy K.M., Diepart C., Jordan B.F., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118 (2008) 3930-3942. Tumors contain highly oxygenated (aerobic) and poorly oxygenated (hypoxic) regions, which were thought to utilize glucose for oxidative and glycolytic metabolism, respectively. Sonveaux et al. show that human cancer cells cultured under hypoxic conditions convert glucose to lactate and extrude it (via MCT4), whereas aerobic cancer cells take up lactate (via MCT1) and utilize it for oxidative phosphorylation. When MCT1 is inhibited, aerobic cancer cells take up glucose rather than lactate, and hypoxic cancer cells die as a result of glucose deprivation. Treatment of tumor-bearing mice with an inhibitor of MCT1 retarded tumor growth. MCT1 expression was detected exclusively in non-hypoxic regions of human cancer biopsy samples, and in combination, these data suggest that MCT1 inhibition holds potential as a novel cancer therapy.
13. Kim J.W., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006) 177-185
14. Papandreou I., Cairns R.A., Fontana L., Lim A.L., and Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3 (2006) 187-197
15. Kim J.W., Gao P., Liu Y.C., Semenza G.L., and Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27 (2007) 7381-7393
16. Cairns R.A., Papandreou I., Sutphin P.D., and Denko N.C. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A 104 (2007) 9445-9450
17. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., Gonzalez F.J., and Semenza G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283 (2008) 10892-10903. HIF-1 induces BNIP3, which triggers mitochondrial-selective autophagy as a means of reducing ROS generation under hypoxic conditions.
18. Tracy K., Dibling B.C., Spike B.T., Knabb J.R., Schumacker P., and Macleod K.F. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Mol Cell Biol 27 (2007) 6229-6242
19. Bellot G., Garcia-Medina R., Gounon P., Chiche J., Roux D., Pouysségur J., and Mazure N.M. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 29 (2009) 2570-2581. The authors show in several cancer cell lines that HIF-1 induces autophagy via expression of both BNIP3 and BNIP3L and, in these cells, knockdown of both proteins was required to block hypoxia-induced autophagy.
20. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., and Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129 (2007) 111-122
21. Wilkinson S., O'Prey J., Fricker M., and Ryan K.M. Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev 23 (2009) 1283-1288
22. Papandreou I., Lim A.L., Laderoute K., and Denko N.C. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ 15 (2008) 1572-1581
23. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., and Semenza G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11 (2007) 407-420
24. Dang C.V., Kim J.W., Gao P., and Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 8 (2008) 51-56
25. Shackelford D.B., Vasquez D.S., Corbeil J., Wu S., Leblanc M., Wu C.L., Vera D.R., and Shaw R.J. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A 106 (2009) 11137-11142. The authors connect LKB1 loss of function with mTOR and HIF-1 gain of function, glucose uptake and gastrointestinal neoplasia.
26. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., and Pandolfi P.P. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785
27. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
28. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
29. Brugarolas J., and Kaelin Jr. W.G. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6 (2004) 7-10
30. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
31. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601
32. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
33. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8 (2005) 143-153
34. Koivunen P., Hirsilä M., Remes A.M., Hassinen I.E., Kivirikko K.I., and Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282 (2007) 4524-4532
35. Hewitson K.S., Liénard B.M., McDonough M.A., Clifton I.J., Butler D., Soares A.S., Oldham N.J., McNeill L.A., and Schofield C.J. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 282 (2007) 3293-3301
36. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324 (2009) 261-265. Missense mutations in the IDH1 gene occur in secondary glioblastoma and impair the enzyme's affinity for its substrate. Forced expression of mutant IDH1 in cultured cells reduces formation of the enzyme product, α-ketoglutarate, and thereby increases HIF-1α levels.
37. Sun W., Zhou S., Chang S.S., McFate T., Verma A., and Califano J.A. Mitochondrial mutations contribute to HIF-1α accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenase kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res 15 (2009) 476-484
38. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., Bhujwalla Z.M., Felsher D.W., Cheng L., Pevsner J., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (2007) 230-238
39. McFate T., Mohyeldin A., Lu H., Thakar J., Henriques J., Halim N.D., Wu H., Schell M.J., Tsang T.M., Teahan O., et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 283 (2008) 22700-22708. The authors provide evidence of a feed-forward mechanism in which increased HIF-1 activity induces expression of PDK1, which alters levels of glycolytic metabolites, which in turn further increase HIF-1 activity.
40. Qing G., and Simon M.C. Hypoxia inducible factor-2α: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 19 (2009) 60-66
41. -/- mice. Nat Genet 35 (2003) 331-340
42. Dioum E.M., Chen R., Alexander M.S., Zhang Q., Hogg R.T., Gerard R.D., and Garcia J.A. Regulation of hypoxia-inducible factor 2α signaling by the stress-responsive deacetylase sirtuin 1. Science 324 (2009) 1289-1293. The authors show that SIRT1 is a positive regulator of HIF-2α. It appears that SIRT1 can have oncogenic or tumor suppressor effects, depending upon the particular context [46], as is also true for HIF-2α [47].
43. Elser M., Borsig L., Hassa P.O., Erener S., Messner S., Valovka T., Keller S., Gassmann M., and Hottiger M.O. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 6 (2008) 282-290
44. Quintero M., Brennan P.A., Thomas G.J., and Moncada S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: role of free radical formation. Cancer Res 66 (2006) 770-774
45. Nanni S., Benvenuti V., Grasselli A., Priolo C., Aiello A., Mattiussi S., Colussi C., Lirangi V., Illi B., D'Eletto M., et al. Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119 (2009) 1093-1108. The authors demonstrate that overexpressed and nuclear-localized endothelial NOS promotes the transcriptional activity of ER-β, HIF-1α, and HIF-2α, which cooperate to activate transcription of genes associated with poor prognosis in prostate cancer. The study is an elegant blend of clinical and molecular approaches. The immunohistochemical and gene expression analyses described in this study could be used to identify prostate cancer patients who might be particularly likely to benefit from treatment with NOS and/or HIF-1 inhibitors.
46. Boily G., He X.H., Pearce B., Jardine K., and McBurney M.W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28 (2009) 2882-2893
47. Imamura T., Kikuchi H., Herraiz M.T., Park D.Y., Mizukami Y., Mino-Kenduson M., Lynch M.P., Rueda B.R., Benita Y., Xavier R.J., et al. HIF-1α and HIF-2α have divergent roles in colon cancer. Int J Cancer 124 (2009) 763-771